# Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck

> **NCT00003182** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hope Cancer Institute, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00003182
- **Lead sponsor:** Hope Cancer Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003182, "Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*